Zydus Lifesciences Limited reported a 30 per cent year-on-year increase in net profit to ₹1,023.5 crore for the quarter ended December 31, 2024, driven by robust performance in its US formulations business. The Ahmedabad-based pharmaceutical company’s revenue from operations grew 17 per cent to ₹5,269.1 crore compared to the same period last year.

The shares of Zydus Lifesciences Limited were trading at ₹977.45, up by ₹3.45 or 0.35 per cent on the NSE today at 2.30 pm.

The company’s US formulations business, which accounts for 47 per cent of consolidated revenues, saw a significant 31 per cent growth to ₹2,409.6 crore. During the quarter, Zydus launched five new products in the US market, including three brands of Sitagliptin.

The India business, contributing 38 per cent of total revenues, recorded a 7 per cent growth to ₹1,947 crore. The company’s consumer wellness segment grew 13 per cent year-on-year with 4.8 per cent volume growth.

EBITDA for the quarter rose 26 per cent to ₹1,387.6 crore, with margins improving by 180 basis points to 26.3 per cent. The company maintained a strong financial position with net cash of ₹3,091.6 crore as of December 31, 2024.

In a significant development for its research pipeline, Zydus received FDA approval to conduct Phase II(b) clinical trials of Usnoflast for Amyotrophic Lateral Sclerosis (ALS), which has also received Orphan Drug Designation from the regulator.

Published on February 5, 2025